Latest / This Is Why with Dr. Busti
PARADIGM-HF Trial: Why Sacubitril/Valsartan Changed HFrEF Care
Dr. Busti explains why the PARADIGM-HF trial changed treatment for heart failure with reduced ejection fraction (HFrEF), connecting sacubitril/valsartan to the clinical evidence behind angiotensin receptor-neprilysin inhibitor (ARNI) therapy.
Why replace an ACE inhibitor in a patient who seems stable? Follow the rationale for neprilysin inhibition, the role of natriuretic peptides, and the reason sacubitril is paired with valsartan. Then examine the comparison with enalapril: cardiovascular death or first heart-failure hospitalization, relative versus absolute benefit, symptomatic…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.